Merus (NASDAQ:MRUS) Given Consensus Recommendation of “Buy” by Analysts

Shares of Merus (NASDAQ:MRUS) have been given an average rating of “Buy” by the sixteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Fourteen analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $85.92.

Several equities analysts recently commented on MRUS shares. Piper Sandler started coverage on Merus in a research report on Thursday, February 13th. They set an “overweight” rating and a $84.00 target price for the company. The Goldman Sachs Group started coverage on Merus in a research report on Thursday, November 21st. They set a “buy” rating and a $73.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $85.00 target price on shares of Merus in a research report on Monday, December 9th. Citigroup boosted their target price on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, UBS Group initiated coverage on Merus in a research report on Thursday, October 24th. They set a “buy” rating and a $72.00 target price for the company.

Merus Stock Up 5.7 %

Merus stock opened at $47.63 on Friday. Merus has a 52 week low of $37.77 and a 52 week high of $61.61. The business has a 50-day simple moving average of $41.63 and a 200 day simple moving average of $46.97. The stock has a market cap of $3.26 billion, a price-to-earnings ratio of -12.06 and a beta of 1.11.

Institutional Investors Weigh In On Merus

Institutional investors have recently bought and sold shares of the stock. State of Wyoming purchased a new stake in Merus during the 4th quarter valued at about $48,000. Wells Fargo & Company MN boosted its holdings in Merus by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 300 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Merus during the 4th quarter valued at about $60,000. Avior Wealth Management LLC purchased a new stake in Merus during the 4th quarter valued at about $76,000. Finally, Lazard Asset Management LLC purchased a new stake in Merus during the 4th quarter valued at about $84,000. 96.14% of the stock is currently owned by hedge funds and other institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.